Skip to main content
PGEN
NASDAQ Life Sciences

Controlling Shareholder Randal J. Kirk Sells $15.6M in Precigen Stock, Reducing Stake

Analysis by Wiseek AI
Sentiment info
Negative
Importance info
9
Price
$3.86
Mkt Cap
$1.37B
52W Low
$1.11
52W High
$5.465
Market data snapshot near publication time

Summary

Randal J. Kirk, the controlling shareholder of Precigen, Inc., through affiliated entities, sold 4.77 million shares of common stock for approximately $15.6 million, reducing his beneficial ownership from approximately 37.2% to 35.9%.


Key Events

  • Significant Share Sale

    Entities controlled by Randal J. Kirk sold 4,772,781 shares of Precigen common stock in open market transactions on March 30, 2026.

  • Substantial Proceeds

    The sale generated approximately $15,581,221 in net proceeds for the selling entities.

  • Reduced Ownership Stake

    This transaction decreased Randal J. Kirk's beneficial ownership from approximately 37.2% to 35.9% of the company's outstanding shares (including exercisable derivatives).


Analysis

This Schedule 13D/A reports a significant disposition of shares by Randal J. Kirk, the company's controlling shareholder. The sale of over $15.5 million worth of stock, representing approximately 1.14% of the company's market capitalization, is a material event. While the filing notes Kirk's continued beneficial ownership of 35.9% (including exercisable warrants and options), this reduction in his stake could be interpreted by investors as a signal, especially following the recent 10-K filing which reported a substantial net loss for 2025. Investors will likely monitor future filings for further changes in insider holdings.

At the time of this filing, PGEN was trading at $3.86 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.4B. The 52-week trading range was $1.11 to $5.47. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

PGEN - Latest Insights

PGEN
May 13, 2026, 4:22 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $4.14
Real-time Price: $4.51 info
Change: +$0.3676 (+9%) info
Market Cap: $1.586B info
PGEN
May 13, 2026, 4:20 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $4.14
Real-time Price: $4.51 info
Change: +$0.3676 (+9%) info
Market Cap: $1.586B info
PGEN
May 13, 2026, 4:05 PM EDT
Source: PR Newswire
Importance Score:
8
Price at Filing: $4.26
Real-time Price: $4.51 info
Change: +$0.2476 (+6%) info
Market Cap: $1.586B info
PGEN
Apr 07, 2026, 7:00 AM EDT
Source: Access Newswire
Importance Score:
9
Price at Filing: $4.10
Real-time Price: $4.51 info
Change: +$0.4076 (+10%) info
Market Cap: $1.586B info
PGEN
Mar 31, 2026, 4:10 PM EDT
Filing Type: 4
Importance Score:
9
Price at Filing: $3.89
Real-time Price: $4.51 info
Change: +$0.6176 (+16%) info
Market Cap: $1.586B info
PGEN
Mar 31, 2026, 4:01 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
9
Price at Filing: $3.86
Real-time Price: $4.51 info
Change: +$0.6476 (+17%) info
Market Cap: $1.586B info
PGEN
Mar 25, 2026, 4:54 PM EDT
Filing Type: 10-K
Importance Score:
8
Price at Filing: $3.67
Real-time Price: $4.51 info
Change: +$0.8376 (+23%) info
Market Cap: $1.586B info
PGEN
Mar 25, 2026, 4:53 PM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $3.32
Real-time Price: $4.51 info
Change: +$1.19 (+36%) info
Market Cap: $1.586B info
PGEN
Mar 25, 2026, 4:52 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.67
Real-time Price: $4.51 info
Change: +$0.8376 (+23%) info
Market Cap: $1.586B info
PGEN
Mar 25, 2026, 4:05 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $2.90
Real-time Price: $4.51 info
Change: +$1.61 (+55%) info
Market Cap: $1.586B info